Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
07:30am, Monday, 25'th Aug 2025
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert
05:30pm, Tuesday, 19'th Aug 2025
Aquinas Wealth Advisors CEO Chris McMahon discusses the state of the economy, the success of healthcare stocks and more on ‘Making Money.' #foxbusiness #fox #usa #us #news #breakingnews #MakingMoney
BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript
04:30am, Saturday, 09'th Aug 2025
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Ananth Sridhar - Chief Operating Officer Chinmay Shukla - VP IR & Strategic Financ
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates
06:26pm, Tuesday, 05'th Aug 2025
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $1.02 per share a year ago.
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
04:01pm, Tuesday, 05'th Aug 2025
- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial tr
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
11:05am, Tuesday, 29'th Jul 2025
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously pub
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
07:30am, Tuesday, 22'nd Jul 2025
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
It is time for a move higher in biotech, says Mizuho's Jared Holz
06:29pm, Monday, 07'th Jul 2025
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
07:30am, Monday, 30'th Jun 2025
PALO ALTO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
07:30am, Thursday, 26'th Jun 2025
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio: New Data Bolsters The Bull Case
03:34am, Wednesday, 04'th Jun 2025
BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvutt
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
07:30am, Monday, 02'nd Jun 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
07:30am, Tuesday, 20'th May 2025
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup w
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever bett
